Skip to main content
HoldModerate Confidence
Investment thesis

Sanofi is a large pharmaceutical company with strong 16% operating margins, 221% free cash flow conversion, and 3 of 4 recent earnings beats, but faces a confirmed death cross with falling on-balance volume and a dividend payout ratio of 552% that appears structurally unsustainable.

Thesis pillars

  • Strong Margins Exceptional Cash Conversion→Stable
  • Three Consecutive Earnings Beats↑Improving
  • Death Cross Confirmed Downtrend↓Deteriorating
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026· older than 90 days

Full reasoning →

Open full analysis

Sanofi (SNY) Stock Analysis

Recovery setup

HoldValueGrowthModerate Confidence

Healthcare · Drug Manufacturers - General

Hold if already holding. Not a fresh buy at $48.39, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 89).

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus... Read more

$48.39-1.3% A.UpsideScore 6.1/10#1 of 16 Drug Manufacturers - General
QualityF-score8 / 9FCF yield7.12%
IncomeYield5.00%(5y avg 4.04%)Payout119.86%at-risk
Stop $46.17Analyst target $47.78(reached)A.R:R -0.1:1
Analyst consensus$54.92+13.5%9 analysts with price targets
$48.39price
$54.92mean
$45
$63

Hold if already holding. Not a fresh buy at $48.39, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 89). Chart setup: Death cross but MACD improving, RSI 89. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Oct 27, 2026

Recent Developments — Sanofi

Latest item Oct 27, 2026 · Generated 2026-11-17T11:37:52Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jan 28, 202772d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Outperforming peers
Wide economic moat
Risks
Analyst target reached - limited upside remaining
Overbought (RSI 89)

Key Metrics

P/E (TTM)24.1
P/E (Fwd)8.9
Mkt Cap$116.2B
EV/EBITDA8.8
Profit Mgn8.2%
ROE5.7%
Rev Growth15.7%
Beta0.26
Dividend5.00%
Analysts with ratings31

Quality Signals

Piotroski F8/9MoatWide

Options Flow

P/C1.40bearish
IV46%normal
Max Pain$25-48.3% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

10 dimensions · all in-band

GatesA.R:R -0.1=NEGATIVEDeath cross (50MA < 200MA)Momentum 6.2>=5.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 72d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
89 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $40.56Resistance $48.98

Price Targets

A.Upside-1.3%
A.R:R-0.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCautious

Risk Alerts

! Target reached (-1.3% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-01-28 (72d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SNY stock a buy right now?

Hold if already holding. Not a fresh buy at $48.39, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 89). Chart setup: Death cross but MACD improving, RSI 89. Maintain position. Not compelling to add more. Analyst target $47.78 reached (−1.3%), stop $46.17 (−4.8%), A.R:R -0.1:1. Score 6.1/10, moderate confidence.

What is the SNY stock price target?

Analyst target $47.78 reached (−1.3% from $48.39); no take-profit level is published. Analyst target $47.78 reached (−1.3%), stop $46.17 (−4.8%), A.R:R -0.1:1. Stop-loss: $46.17.

What are the risks of investing in SNY?

Analyst target reached - limited upside remaining; Overbought (RSI 89).

Is SNY overvalued or undervalued?

Sanofi trades at a P/E of 24.1 (forward 8.9). TrendMatrix value score: 6.4/10. Verdict: Hold.

What do analysts say about SNY?

31 analysts rate SNY, with a consensus score of 3.8/5. 9 analysts publish price targets averaging $55.

What does Sanofi do?Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and...

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Related stocks: BMY (Bristol-Myers Squibb Company) · AZN (AstraZeneca PLC) · BIIB (Biogen Inc.) · NVO (Novo Nordisk A/S) · ABBV (AbbVie Inc.)
Home › Stocks › SNY

Latest news

Latest News

TipRanks111d agoEarnings
TipRanks111d agoEarnings
TipRanks111d agoEarnings
GuruFocus209d ago
Benzinga209d agoFda Decision
Seeking Alpha209d agoFda Decision
MarketBeat216d ago
TipRanks216d agoProduct
Seeking Alpha132d agoLegal
Yahoo Finance223d agoAnalyst
GuruFocus112d ago
Ad-hoc-news.de21d ago
Investing.com South Africa119d agoRestructuring
Moomoo119d agoRestructuring
Quiver Quantitative119d ago
Meyka210d agoEarnings
Quiver Quantitative210d ago
GuruFocus28d ago
Pluang28d ago
Seeking Alpha28d ago
Loading more...